Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer - Wikidata - wikimedia - TriplyDB

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

http://www.wikidata.org/entity/Q33877542

about

Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.The Treatment of Localized Prostate Cancer in Everyday Practice in Germany Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Contemporary management of men with high-risk localized prostate cancer in the United States.Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan.Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant)The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer.Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.Endogenous testosterone and mortality risk.Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients.[Cardiovascular risks of androgen deprivation therapy for prostate cancer].Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).

P2860

Q26797063-49E18E2C-78A4-404B-921A-4EC7619789EA Q33900049-C4966AD5-1053-4F17-9EC3-E1204E83C4F9 Q33919551-4CABEC74-282A-4E74-9C5B-C60D713D9354 Q35870468-F45F3346-19F9-4EAD-AA58-196AC656BA49 Q36067956-C0D79CD1-7D19-4F14-A2A4-E967A2BA0C8E Q36568781-075E2DE0-A505-4BD3-B4FB-0FD4B2C32AC8 Q36996753-1FAA44A2-AC2F-4FA4-AEEC-5B1E959122FE Q37609253-2771F274-C422-4087-B6E2-CEBBEFC74353 Q37708169-B7C785C0-FBA8-4CC6-B382-304EE0ABE0F0 Q38261253-A11607D2-CE90-4078-8342-F691840FC9EB Q38717765-796D097B-782C-4FD9-B7D4-313460C76DE1 Q38736557-C6414125-7355-4167-9361-EB260C2C3872 Q38804659-14A9CC29-3CC0-48AE-BE49-D7E465B8117D Q38822554-A468AA99-EAFF-4146-A4D8-11FC6034D87A Q40834657-8B79E0F3-01B7-4C69-9A73-A0295132E871 Q47642912-C13F881F-677A-4254-AC34-F3941AC69FDD Q52617229-D3CF99A7-1092-4A0F-8EEC-7528F7ADBB6D Q52854661-EA075AB6-0DFF-4DD5-928E-36D134DF4DCA Q53734447-555EF668-CAAF-4FFA-9852-59CBD2554D8E

P2860

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

http://www.wikidata.org/entity/Q33877542

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Fifteen-year survival outcomes ...... for localized prostate cancer

@ast

Fifteen-year survival outcomes ...... for localized prostate cancer

@en

type

label

Fifteen-year survival outcomes ...... for localized prostate cancer

@ast

Fifteen-year survival outcomes ...... for localized prostate cancer

@en

prefLabel

Fifteen-year survival outcomes ...... for localized prostate cancer

@ast

Fifteen-year survival outcomes ...... for localized prostate cancer

@en

P1433

Q33877542-8C00D7A3-59EF-4EFA-976E-C2D09C4DDC52

P1476

Q33877542-776F8744-74C6-49B6-9114-1FE6EB74682E

P2093

Q33877542-2745CF6E-938E-4493-9A37-E14641EB8383

Q33877542-2F10C84B-634C-4169-92FD-CBEAFC8DCBF6

Q33877542-43E93AB5-3AB1-491D-904A-66096D04302D

Q33877542-77CAD345-FB14-45AA-B967-78F1E6314BD9

Q33877542-8FCB81C9-F21C-4BA1-B9D8-3438B7FB4997

Q33877542-91D93556-DC2A-47AB-BD84-84C5B44F55F6

Q33877542-DECF3B9B-DF08-4794-BDD5-1DFCAD55633D

P2860

Q33877542-0DD3FC2E-C1B9-489C-9A49-44A258FFEB74

Q33877542-0FD858A7-5B54-4773-8DDE-3D230C7E7F75

Q33877542-1938ABAB-3F8D-4EF4-9309-69FE9899CB37

Q33877542-264BE282-2BC2-4F80-A872-A4C6E50AACB8

Q33877542-269D74FD-477E-4222-95D5-EFBD29BF3154

Q33877542-4C55F76A-704D-4BC4-94C1-B7F02C30D1B9

Q33877542-501B652D-BA66-4B75-8059-FAF64BCBB8AD

Q33877542-533FCD25-B825-47E0-8F02-8B8C3B611E4C

Q33877542-94D213A9-4297-44B4-B9DB-083A6EE45708

Q33877542-993DCEB9-BFF5-4EF4-84E0-253B8CF00A81

P304

Q33877542-8B16A024-6944-43DA-AFE3-C6933866CB0D

P31

Q33877542-246A70C4-D5E9-4F01-A945-D34EDF60A824

P356

Q33877542-C48E0600-0BD0-4537-A14F-494E432C29A5

P433

Q33877542-8F723A19-B53E-4D8F-B9E6-019F79F845D4

P478

Q33877542-88402B07-2AFF-47BE-9382-0CCEDD9E3093

P577

Q33877542-A5F85548-494B-4905-A1D5-CBAE49A5B060

P698

Q33877542-E62EEBF6-5284-4C9C-A2E6-38E89BCD1AD4

P932

Q33877542-DB9F653B-DF18-4194-93AB-5C827E046EB0

P356

JAMAINTERNMED.2014.3028

P1433

JAMA Internal Medicine

P1476

Fifteen-year survival outcomes ...... for localized prostate cancer

@en

P2093

Dirk F Moore

http://www.w3.org/2001/XMLSchema#string

Grace L Lu-Yao

http://www.w3.org/2001/XMLSchema#string

Peter C Albertsen

http://www.w3.org/2001/XMLSchema#string

Robert S DiPaola

http://www.w3.org/2001/XMLSchema#string

Siu-Long Yao

http://www.w3.org/2001/XMLSchema#string

Weichung Shih

http://www.w3.org/2001/XMLSchema#string

Yong Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a comorbidity index using physician claims data.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

P304

1460-1467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAINTERNMED.2014.3028

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25023796

http://www.w3.org/2001/XMLSchema#string

P932

5499229

http://www.w3.org/2001/XMLSchema#string